Diagnosis and Management of Infantile Hemangioma

More documents

Recommendations

Info

Table A-3. EMBASE search strategies (OvidSP interface) Search Terms #1 Capillary hemangioma / or infantile hemangioma.tw. or infantile hemangiomas.tw. or infantile haemangioma.tw. or infantile haemangiomas.tw. or haemangioma.tw. or hemangiomas.tw. or IH.tw. #2 Infant/ or child/ or newborn/ or congenital disorder/ or infant*.tw. or infantile.tw. or child.tw. or children.tw. or newborn.tw. or newborns.tw. Search Results 15,518 2,257,155 #3 1 AND 2 4658 #4 Limit 3 to English 3782 #5 Limit 4 to human 3392 #6 5 not (editorial.pt. or letter.pt. or note.pt. or short survey.pt. or conference 3155 paper.pt.) #7 Limit 6 to exclude MEDLINE journals 236 Key: / Emtree heading; .tw. abstract, title <strong>and</strong> drug trade name; /cn congenital; .fs. subheading; si.fs. side effects subheading; th.fs. therapy subheading; su.fs. surgery subheading; co.fs. complications subheading; pt. publication type A-2
Searches for Comparative Effectiveness Questions Table A-4. MEDLINE (PubMed) Search Terms Search Results #1 hemangioma[mh] OR hemangioma, capillary infantile[nm] OR infantile hemangioma*[tiab] OR infantile haemangioma*[tiab] OR capillary hemangioma*[tiab] OR capillary haemangioma*[tiab] OR congenital hemangioma*[tiab] OR congenital haemangioma*[tiab] OR IH[tiab] #2 infant[mh] OR infant[tiab] OR infants[tiab] OR infantile[tiab] OR pediatric[tiab] OR neonat*[tiab] OR child[mh] OR children[tiab] OR youth[tiab] 33,062 2,335,431 #3 Therapeutics[mh] OR therapy[sh] OR Treatment Outcome[mh] OR therapy[tiab] OR 10,334,120 therapies[tiab] OR therapeutic[tiab] OR therapeutics[tiab] OR outcome[tiab] OR outcomes[tiab] OR surgical[tiab] OR surgery[sh] OR surgery[tiab] OR Embolization, Therapeutic[mh] OR embolization[tiab] OR embolization[tiab] OR cryotherapy[mh] OR cryotherapy[tiab] OR Catheter Ablation[mh] OR radi<strong>of</strong>requency ablation[tiab ]OR Laser, dye [mh] OR Laser, Gas/therapeutic use[mh] OR Laser Therapy[mh] OR “carbon dioxide laser”[tiab] OR “carbon dioxide lasers”[tiab] OR CO2 laser[tiab] OR CO2 lasers[tiab] OR “fractionated laser”[tiab] OR “fractionated lasers”[tiab] OR argon[tiab] OR Lasers, Solid-State[mh] OR Neodymium YAG[tiab] OR YAG[tiab] OR Erbium[tiab] OR Propranolol[mh] OR propranolol[tiab] OR Timolol[mh] OR timolol[tiab] OR Imiquimod[NM] OR Adrenergic beta-Antagonists[mh] OR Angiotensin-converting enzyme inhibitors[mh] OR Immunosuppressive agents[mh] OR Angiogenesis Inhibitors[mh] OR Bleomycin[mh] OR bleomycin[tiab] OR Antineoplastic agents[mh] OR Vincristine[mh] OR vincristine[tiab] OR corticosteroids[tiab] OR beta-blockers[tiab] OR beta blockers[tiab] OR beta blocker[tiab] OR beta-blockers[tiab] OR angiotensin[tiab] OR intralesional interferon[tiab] OR “adverse effects"[Subheading] OR unsafe[tiab] OR safety[tiab] OR harm[tiab] OR harms[tiab] OR harmful[tiab] OR complication[tiab] OR complications[tiab] OR side-effect[tiab] OR "side-effects"[tiab] OR Undesirable effect[tiab] OR undesirable effects[tiab] OR undesirable reaction[tiab] OR undesirable reactions[tiab] OR undesirable event[tiab] OR undesirable events[tiab] OR undesirable outcome[tiab] OR undesirable outcomes[tiab] OR adverse effect[tiab] OR adverse effects[tiab] OR adverse reaction[tiab] OR adverse reactions[tiab] OR adverse event[tiab] OR adverse events[tiab] OR adverse outcome[tiab] OR adverse outcomes[tiab] OR "Postoperative Complications"[Mesh] OR postoperative complication[tiab] OR postoperative complications[tiab] OR post operative complication[tiab] OR post operative complications[tiab] OR surgical complication[tiab] OR surgical complications[tiab] OR postsurgical complication[tiab] OR postsurgical complications[tiab] OR post surgical complication[tiab] OR post surgical complications[tiab] OR adverse effects[Subheading] OR complications[Subheading] OR contraindications[Subheading] OR bleeding[tiab] OR Hemorrhage[mh] OR scarring[tiab] OR scars[tiab] OR residual hemangiomas[tiab] OR residual hemangioma[tiab] OR residual haemangioma[tiab] OR residual haemangiomas[tiab] OR pain[mh] OR pain[tiab] OR “Skin atrophy”[tiab] OR venous prominence[tiab] OR facial injuries[mh] OR skin ulcer[mh] OR ulceration[tiab] OR “surgical wound infection”[mh] OR wound infection[mh] OR infection[tiab] #4 #1 AND #2 AND #3 7392 #5 #4 AND eng[la] 5441 #6 #5 AND Humans[mh] 5203 #7 #6 AND ("1982/01/01"[Date - Publication] : "3000"[Date - Publication]) 4358 #8 #7 NOT (editorial[pt] OR letter[pt] OR comment[pt] OR review[pt] OR news[pt] OR 3409 historical article[pt] OR practice guideline[pt] OR meta-analysis[pt]) Key: [mh] medical subject heading; [nm] supplementary concept; [tiab] keyword in title or abstract; [la] language; [pt] publication type; [sh] subheading A-3
Page 1 and 2:
Comparative Effectiveness Review Nu
Page 3 and 4:
This report is based on research co
Page 5 and 6:
Acknowledgments The authors gratefu
Page 7 and 8:
Peer Reviewers Prior to publication
Page 9 and 10:
BCI; moderate SOE for effects of pr
Page 11 and 12:
Overview of the Literature ........
Page 13 and 14:
Executive Summary Introduction Infa
Page 15 and 16:
for contextual questions as few eff
Page 17 and 18:
Figure B. Analytic framework for KQ
Page 19 and 20:
Table A. Inclusion criteria (contin
Page 21 and 22:
precision (precise, imprecise), and
Page 23 and 24:
Figure D. Estimates of expected IH
Page 25 and 26:
majority of studies to date have in
Page 27 and 28:
effectiveness outcomes. The evidenc
Page 29 and 30:
changes. We considered the strength
Page 31 and 32:
Table C. Summary of evidence in stu
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Table D. Summary of evidence in stu
Page 39 and 40:
Applicability We set inclusion crit
Page 41 and 42:
quantitative meta-analyses. Researc
Page 43 and 44:
surgically. Lesion characteristics
Page 45 and 46:
References 1. Wassef M, Blei F, Ada
Page 47 and 48:
39. Yu L, Li S, Su B, et al. Treatm
Page 49 and 50:
modalities. The questions of imagin
Page 51 and 52:
KQ2. Among newborns, infants, and c
Page 53 and 54:
of data, and compiling evidence. We
Page 55 and 56:
We only included studies published
Page 57 and 58:
a standardized form (Appendix B) th
Page 59 and 60:
Determining Quality Ratings • We
Page 61 and 62:
Results We present results for Cont
Page 63 and 64:
defects, urogenital anomalies, ulce
Page 65 and 66:
Results of Literature Searches for
Page 67 and 68:
Table 3. Characteristics of include
Page 69 and 70:
scans, had a sensitivity of 20 perc
Page 71 and 72:
of the model fit to all studies, bu
Page 73 and 74:
Detailed Analysis Effectiveness of
Page 75 and 76:
Table 6. Key resolution outcomes in
Page 77 and 78:
with prednisolone included endocrin
Page 79 and 80:
children in 8 studies), skin atroph
Page 81 and 82:
hypopigmentation, impaired wound he
Page 83 and 84:
fair quality for effectiveness outc
Page 85 and 86:
studies of nadolol and atenolol. No
Page 87 and 88:
Table 10. Key resolution outcomes i
Page 89 and 90:
old. 100 Thirty percent of children
Page 91 and 92:
Table 11. Resolution outcomes in st
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Table 15. Key outcomes in studies c
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Table 22. Harms/adverse effects in
Page 109 and 110:
Table 24. Adverse effects in case s
Page 111 and 112:
Table 24. Adverse effects in case s
Page 113 and 114:
• In two RCTs reporting level of
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Nd:YAG Laser With Cooling Compared
Page 121 and 122: Table 30. Key resolution outcomes i
Page 123 and 124: long term follow information was av
Page 125 and 126: Discussion State of the Literature
Page 127 and 128: Table 34. Strength of evidence for
Page 131 and 132: Effectiveness and Harms of Beta-Blo
Page 149 and 150: older children. One comparative stu
Page 151 and 152: case series reporting on rarer pres
Page 153 and 154: agents is critical, especially as u
Page 155 and 156: References 1. Wassef M, Blei F, Ada
Page 157 and 158: 39. Chen TS, Eichenfield LF, Friedl
Page 159 and 160: 80. Mai HM, Zheng JW, Wang YA, et a
Page 161 and 162: 119. Sharma LK, Dalal SS. Corticost
Page 163 and 164: 162. Snir M, Reich U, Siegel R, et
Page 165 and 166: 198. Chen ZG, Zheng JW, Yuan ML, et
Page 167 and 168: 237. Healy G, McGill T, Friedman EM
Page 169 and 170: Abbreviations and Acronyms Used in
Page 171: Appendix A. Search Strategies Searc
Page 175 and 176: Appendix B. Screening and Quality A
Page 177 and 178: Harms Risk of Bias Assessment Form
Page 179 and 180: QUADAS Diagnostic Accuracy Rating T
Page 181 and 182: Infantile Hemangioma CER: Risk of B
Page 183 and 184: 20. Grundfest-Broniatowski S, Carey
Page 185 and 186: 65. Dachman AH, Lichtenstein JE, Fr
Page 187 and 188: 111. Yoshida T, Kuratomi K, Mitsuma
Page 189 and 190: 160. Newman SL, Goodwin CD. Colonic
Page 191 and 192: 204. Crockett DM, Healy GB, McGill
Page 193 and 194: 253. Wright GL, Smith RJ, Katz CD,
Page 195 and 196: 301. Paley D, Jackson RW. Synovial
Page 197 and 198: 346. Dombrowski MP, Budev H, Wolfe
Page 199 and 200: 390. Stringel G. Giant hemangioma:
Page 201 and 202: 436. Liu HC, Chang MH, Lue HC, et a
Page 203 and 204: 480. Casale AJ, Menashe DS. Massive
Page 205 and 206: 526. Taylor RS, Joseph DB, Kohaut E
Page 207 and 208: 571. Goldstein MH. The elastic flap
Page 209 and 210: 614. Salloum E, Flamant F, Caillaud
Page 211 and 212: 659. Fellows KE, Hoffer FA, Markowi
Page 213 and 214: 706. Weatherford DA, Abrams RS, Wal
Page 215 and 216: 749. Keleti D, Flickinger JC, Hobso
Page 217 and 218: 793. Van Campenhout I, Patriquin H.
Page 219 and 220: 836. Goldman MP, Fitzpatrick RE, Ru
Page 221 and 222: 880. Schulman SR, Jones BR, Slotnic
Page 223 and 224:
924. Egawa H, Berquist W, Garcia-Ke
Page 225 and 226:
968. Thompson DN, Taylor WF, Haywar
Page 227 and 228:
1013. Gregg CM, Wiatrak BJ, Koopman
Page 229 and 230:
1056. Rozylo TK, Krupski W, Galkows
Page 231 and 232:
1099. Fremont S, Kanny G, Bieber S,
Page 233 and 234:
1142. Sreeram N, Miller P, John P.
Page 235 and 236:
1185. Enjolras O, Wassef M, Mazoyer
Page 237 and 238:
1228. Paley MR, Farrant P, Kane P,
Page 239 and 240:
1271. Burrows PE, Robertson RL, Mul
Page 241 and 242:
1312. Lezama-del Valle P, Gerald WL
Page 243 and 244:
1352. Altunay IK, Gokdemir G, Koken
Page 245 and 246:
1394. Kiristioglu I, Kilic N, Gurpi
Page 247 and 248:
1437. Yoshida D, Sugisaki Y, Shimur
Page 249 and 250:
1480. Kreusel KM, Bechrakis NE, Hei
Page 251 and 252:
1523. Wilken JJ, Meier FA, Kornstei
Page 253 and 254:
1568. Garmendia G, Miranda N, Borro
Page 255 and 256:
1610. Park EA, Seo JW, Lee SW, et a
Page 257 and 258:
1652. Chatrath P, Black M, Jani P,
Page 259 and 260:
1694. Hopf M, Hopf JUG, Rohde E, et
Page 261 and 262:
1737. Rozylo-Kalinowska I, Brodzisz
Page 263 and 264:
1782. Coras B, Hohenleutner U, Land
Page 265 and 266:
1826. McQueen CT, Cullen RD. Endosc
Page 267 and 268:
1866. Tsao MN, Schwartz ML, Bernste
Page 269 and 270:
1909. Denier C, Labauge P, Brunerea
Page 271 and 272:
1950. Mounayer C, Benndorf G, Bisdo
Page 273 and 274:
1992. Woo SJ, Kim CJ, Yu YS. Cavern
Page 275 and 276:
2036. Ersoy S, Mancini AJ. Hemifaci
Page 277 and 278:
2077. Kronenberg A, Blei F, Ceisler
Page 279 and 280:
2117. Sabharwal GK, Strouse PJ. Pos
Page 281 and 282:
2159. Cannady SB, Kahn TA, Trabouls
Page 283 and 284:
2200. Karikari IO, Selznick LA, Cum
Page 285 and 286:
2241. Pienaar C, Graham R, Geldenhu
Page 287 and 288:
2283. Wananukul S, Voramethkul W, N
Page 289 and 290:
2327. Czernik A, Bystryn JC. Does i
Page 291 and 292:
2368. Kamida T, Takeda Y, Fujiki M,
Page 293 and 294:
2410. Rodgers B, Zeim S, Crawford B
Page 295 and 296:
2453. Zolkipli Z, Aylett S, Rankin
Page 297 and 298:
2495. Egberts F, Mentzel T, Leuschn
Page 299 and 300:
2537. Kutluhan A, Bozdemir K, Ugras
Page 301 and 302:
2580. Saetti R, Silvestrini M, Cutr
Page 303 and 304:
2620. Yun TJ, Na DG, Kwon BJ, et al
Page 305 and 306:
2661. Demirci H, Shields CL, Eagle
Page 307 and 308:
2700. Iriz A, Durmaz E, Akmansu SH,
Page 309 and 310:
2744. Ooi KG, Wenderoth JD, Francis
Page 311 and 312:
2786. Tyzio R, Khalilov I, Represa
Page 313 and 314:
2827. Bayliss SJ, Berk DR, Van Hare
Page 315 and 316:
2869. Fernandez-Pineda I, Lopez-Gut
Page 317 and 318:
2910. Kazim SF, Bhatti, Enam SA. In
Page 319 and 320:
2953. Nonogaki S, Campos HGA, Butug
Page 321 and 322:
2995. Storch CH, Hoeger PH. Propran
Page 323 and 324:
3038. Al Dhaybi R, Superstein R, Mi
Page 325 and 326:
3080. del Pozo J, Lopez-Gutierrez J
Page 327 and 328:
3120. Guye E, Chollet-Rivier M, Sch
Page 329 and 330:
3159. Kolokythas A, Al-Ghamian H, M
Page 331 and 332:
3201. Nale P. Propranolol treatment
Page 333 and 334:
3243. Soltani AM, Reinisch JF. Algo
Page 335 and 336:
3286. . Derm Dx. Clinical Advisor.
Page 337 and 338:
3326. Chang YT, Lin JY, Lee JY, et
Page 339 and 340:
3367. Gross BC, Janus JR, Orvidas L
Page 341 and 342:
3407. Kupeli S. Use of propranolol
Page 343 and 344:
3448. Raches D, Hiscock M, Chapiesk
Page 345 and 346:
3490. Traivaree C, Lumkul R, Torcha
Page 347 and 348:
3532. Ammerman RT, Putnam FW, Altay
Page 349 and 350:
3573. Chou S, Subramanian V, Lau HM
Page 351 and 352:
3614. Hyland RM, Komlosi K, Alleman
Page 353 and 354:
3655. Masetti R, Colecchia A, Ronde
Page 355 and 356:
3693. Parikh SR, Darrow DH, Grimmer
Page 357 and 358:
3732. Stiles JM, Amaya C, Rains S,
Page 359 and 360:
3772. Zou HX, Jia J, Zhang WF, et a
Page 361 and 362:
3813. Deng X, Wang K, Wu L, et al.
Page 363 and 364:
3851. Khorsand K, Backus S, Sidbury
Page 365 and 366:
3890. Phillips RJ, Lokmic Z, Crock
Page 367 and 368:
3930. Weil AG, Bhatia S. Resection
Page 369 and 370:
3969. Ravenscroft J. Management of
Page 371 and 372:
where ΦΦ(xx) is the cumulative di
Page 373 and 374:
Figure D-1. Estimates of expected I
Page 375 and 376:
Figure D-3. Posterior SUCRA estimat
Page 377 and 378:
Figure D-5. Network diagram of comp
Page 379 and 380:
Appendix E. Study Design Classifica
Page 381 and 382:
Author, Year Hogeling 2011 10 Alloc
Page 383 and 384:
Author, Year Representativeness of
Page 385 and 386:
Author, Year Were the harms predefi
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
25. Qiu Y, Ma G, Yang J, et al. Imi
Page 399 and 400:
56. Hassan BA, Shreef KS. Propranol
Page 401 and 402:
88. Chakkittakandiyil A, Phillips R
Page 403 and 404:
120. Pandey A, Gangopadhyay AN, Gop
Page 405 and 406:
Appendix G. Applicability Tables Ta
Page 407 and 408:
Appendix H. Harms Reported in Packa
Page 409 and 410:
o Acquired (autoimmune) hemolytic a
Page 411 and 412:
o Ankylosing spondylitis o Dermatom
Page 413 and 414:
H-7 • Increased dosage of rapidly
Page 415 and 416:
Elocon® (mometason e furoate) 11 T
Page 417 and 418:
Timoptic® (timolol maleate) 15 Tim
Page 419 and 420:
Harms Data for Medications Included
Page 421 and 422:
Table H-3: Adverse Events from Flo-
Page 423 and 424:
(
Page 425 and 426:
thromboembolism, thrombophlebitis,
Page 427 and 428:
grades): 103 (48%), erosion/ulcerat
Page 429 and 430:
acute myocardial infarction: 3 (Rat
Page 431 and 432:
Discontinuations Patients utilizing
Page 433 and 434:
ocular irritation including blephar
show all

Diagnosis and Management of Infantile Hemangioma

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?